Dean Moscovic, DO
Internal Medicine · Clarkston, MINPI 1952309718
Payments from drug & device makers
Across 430 payments — averaging $331.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seqirus USA Inc$84K
- Sanofi US Services Inc.$25K
- GSK$17K
- Sanofi Pasteur Inc.$10K
- Modernatx, Inc.$2K
- Novo Nordisk$1K
- plus $4K from 26 others
What the payments were for
- Food & beverage$4,83899%
- Education$391%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seqirus USA Inc | 27 | $84,025 |
| Sanofi US Services Inc. | 3 | $24,606 |
| GSK | 16 | $17,006 |
| Sanofi Pasteur Inc. | 2 | $9,875 |
| Modernatx, Inc. | 1 | $2,400 |
| Novo Nordisk | 99 | $1,147 |
| AbbVie(2 entities) | 68 | $876 |
| Pfizer | 67 | $820 |
| Lilly USA, LLC | 48 | $466 |
| Amgen | 28 | $352 |
| Merck | 24 | $214 |
| AstraZeneca | 8 | $171 |
| Novartis | 9 | $149 |
| Teva Pharmaceuticals USA, Inc. | 4 | $69 |
| E.r. Squibb & Sons, L.L.C. | 4 | $58 |
| Biohaven Pharmaceuticals, Inc. | 3 | $50 |
| Nestle Healthcare Nutrition Inc. | 2 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $30 |
| Hologic Sales And Service, LLC | 1 | $28 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $26 |
| Harmony Biosciences LLC | 1 | $26 |
| Supernus Pharmaceuticals, Inc. | 2 | $24 |
| Abbott | 1 | $24 |
| Axsome Therapeutics, Inc. | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Corium, LLC | 1 | $19 |
| Lucid Diagnostics Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $16 |
| Alk-abello, Inc | 1 | $15 |
| Medtronic | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $12 |
How this compares
$142,632 in reported general payments places this provider in the 95th percentile of 4,567 internal medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 179 | $261,405 |
| OzempicSemaglutide | 159 | $226,625 |
| EliquisApixaban | 180 | $168,315 |
| JardianceEmpagliflozin | 122 | $144,346 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 108 | $95,563 |
| Xeljanz XrTofacitinib Citrate | 16 | $85,510 |
| EnbrelEtanercept | 11 | $78,558 |
| JanuviaSitagliptin Phosphate | 50 | $50,994 |
| XareltoRivaroxaban | 34 | $43,751 |
| TrulicityDulaglutide | 16 | $29,386 |
| EntrestoSacubitril/Valsartan | 21 | $27,305 |
| LinzessLinaclotide | 33 | $26,217 |
| MyrbetriqMirabegron | 36 | $22,547 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $21,097 |
| Novolog FlexpenInsulin Aspart | 50 | $20,721 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $466 | $290,791195 claims |
| Novo NordiskOzempic | $1,147 | $226,625159 claims |
| PfizerEliquis, Nurtec Odt, Premarin | $820 | $188,349211 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $16 | $150,101134 claims |
| GSKTrelegy Ellipta, Shingrix, Anoro Ellipta | $17,006 | $114,073174 claims |
| AmgenEnbrel | $352 | $78,55811 claims |
| MerckJanuvia | $214 | $50,99450 claims |
| NovartisEntresto | $149 | $27,30521 claims |
| AstraZenecaFarxiga, Symbicort | $171 | $26,39745 claims |
| AbbVieLinzess | $876 | $26,21733 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $30 | $8,38014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,567 internal medicine providers in Michigan.
Other internal medicine in Clarkston
- Ulka VaishampayanAnn Arbor$33.7M
- Jeffrey PottsBay City$14.7M
- Neil FraserTroy$14.3M
- Abdulhassan SaadDearborn$11.5M
- Leslie PelkeyGrand Rapids$8.5M
- Jay SandbergTroy$8.3M
- Ding WangDetroit$6.8M
- Dipenkumar ModiDetroit$4.1M
- Ahmed ArifFlint$4.1M
- Sudipto MukherjeeRoyal Oak$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.